Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Koup

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Virology|February 18, 2011
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeThomas W Geisbert, Michael Bailey, Lisa Hensley, et al.
Plos One|May 8, 2015
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trialJulie E Ledgerwood, Abbie R Bellamy, Robert Belshe, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
Journal of Immunological Methods|May 3, 2014
Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trialsAnna Sambor, Ambrosia Garcia, Mark Berrong, et al.
The Journal of Infectious Diseases|November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood SamplesDean Follmann, Lauren Dang, Eric Chu, et al.
Plos One|September 19, 2019
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trialCristina Carter, Katherine V Houser, Galina V Yamshchikov, et al.
Plos One|November 3, 2018
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trialKatherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Virology|February 18, 2011
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeThomas W Geisbert, Michael Bailey, Lisa Hensley, et al.
Plos One|May 8, 2015
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trialJulie E Ledgerwood, Abbie R Bellamy, Robert Belshe, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
Journal of Immunological Methods|May 3, 2014
Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trialsAnna Sambor, Ambrosia Garcia, Mark Berrong, et al.
The Journal of Infectious Diseases|November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood SamplesDean Follmann, Lauren Dang, Eric Chu, et al.
Plos One|September 19, 2019
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trialCristina Carter, Katherine V Houser, Galina V Yamshchikov, et al.
Plos One|November 3, 2018
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trialKatherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Pageof 3